Literature DB >> 16784990

Comparison of allelic losses in chondroblastoma and primary chondrosarcoma of bone and correlation with fluorescence in situ hybridization analysis.

Dionysios J Papachristou1, Mark A Goodman, Katheleen Cieply, Jennifer L Hunt, Uma N M Rao.   

Abstract

Chondroblastoma (CBL) is a benign neoplasm of bone for which the genomic characteristics remain unclear. We compared the status of allelic losses of CBL with that seen in a set of chondrosarcomas (CS) to determine whether differences in their natural history and behavior are also reflected genetically. Eleven cases of CBL and 10 cases of CS of different grades were included. Tumors were subjected to microdissection and polymerase chain reaction using 17 markers located near genes on chromosomes 5, 9, 11, 13, 17, and 19. The selected chromosomes are known to be involved in several mesenchymal neoplasms. Fluorescence in situ hybridization was also performed on tumors displaying allelic losses, with dual-color probes for 9p, 17p, and 13q. Fractional allelic losses per gene ranged from 18.2% to 63.7% in CBLs and from 28.6% to 66.7% in CSs. Loss of heterozygosity (LOH) of 5q, 9p, 11p, 13q, and 19q occurred in both CBLs and CSs. Loss of heterozygosity of 17p (p53 locus) occurred in 7 of 11 CBLs and in only 1 case of recurrent CS. The pattern of allelic loss was similar in low-grade CSs and CBLs. Loci with LOH in both tumor types suggest possible involvement of the genes p53, RB1, CDKN2/p16, ERC, and XRCC in tumorigenesis. Overall correlation between LOH and fluorescence in situ hybridization results was 90% with 17p13, 80% with 9p, and 60% with 13q. The role of p53 in CBL is uncertain; however, given the benign behavior of this tumor, it is probably unrelated to tumor progression.

Entities:  

Mesh:

Year:  2006        PMID: 16784990     DOI: 10.1016/j.humpath.2006.02.014

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  5 in total

1.  Expression of the ribonucleases Drosha, Dicer, and Ago2 in colorectal carcinomas.

Authors:  Dionysios J Papachristou; Angeliki Korpetinou; Efstathia Giannopoulou; Anna G Antonacopoulou; Helen Papadaki; Petros Grivas; Chrisoula D Scopa; Haralabos P Kalofonos
Journal:  Virchows Arch       Date:  2011-07-18       Impact factor: 4.064

2.  Destructive tumours of the larynx mimicking osteosarcoma: two cases of osteoblastoma with organ-saving resection and follow-up.

Authors:  Ansgar Dellmann; Heinz-Georg Schroeder; Konrad Donhuijsen
Journal:  Eur Arch Otorhinolaryngol       Date:  2009-09-17       Impact factor: 2.503

3.  Chondrosarcoma: with updates on molecular genetics.

Authors:  Mi-Jung Kim; Kyung-Ja Cho; Alberto G Ayala; Jae Y Ro
Journal:  Sarcoma       Date:  2011-02-15

4.  SOX9 Knockout Induces Polyploidy and Changes Sensitivity to Tumor Treatment Strategies in a Chondrosarcoma Cell Line.

Authors:  Sabine Stöckl; Georg Lindner; Shushan Li; Philipp Schuster; Sebastian Haferkamp; Ferdinand Wagner; Peter M Prodinger; Gabriele Multhoff; Melanie Boxberg; Axel Hillmann; Richard J Bauer; Susanne Grässel
Journal:  Int J Mol Sci       Date:  2020-10-15       Impact factor: 5.923

5.  Temporal Chondroblastoma with a Novel Chromosomal Translocation (2;5) (q33;q13).

Authors:  Andrew P Carlson; Howard Yonas; Garth T Olson; Kaaren K Reichard; Rafael Medina-Flores
Journal:  Skull Base Rep       Date:  2011-03-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.